Form 4: Amgen CFO Acquires 12,063 Shares in Equity Grant

Amgen's Executive Vice President and Chief Financial Officer, Peter H. Griffith, reported the acquisition of 12,063 shares of common stock through an equity grant.

Summary

• Peter H. Griffith, Executive Vice President and Chief Financial Officer of Amgen Inc., acquired 12,063 shares of Amgen common stock.
• The transaction occurred on March 3, 2026, with a reported acquisition price of $0 per share, indicating an equity grant or vesting event.
• Following this transaction, Griffith beneficially owns a total of 54,587 shares of Amgen common stock.
• The total beneficial ownership includes 676 Dividend Equivalents (DEs) associated with unvested Restricted Stock Units (RSUs), which are paid out in shares on a one-to-one basis according to the vesting schedule.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive and routine filing, reflecting standard executive compensation practices that align management incentives with shareholder interests without indicating any material change in company operations or outlook.

Positives

• The acquisition of 12,063 shares by the EVP & CFO aligns management's interests with those of shareholders, promoting long-term value creation.
• The inclusion of Dividend Equivalents (DEs) on unvested RSUs provides additional value to the executive, reflecting ongoing company performance and further incentivizing retention.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• NA

Industry Context

StockSavvy.ai notes that equity grants, such as Restricted Stock Units (RSUs) with dividend equivalents, are a standard component of executive compensation in the biotechnology and pharmaceutical industry. This practice aims to incentivize long-term performance and align executive interests with shareholder value creation, reflecting common compensation strategies across the sector.

Comparison to Industry Standards

• Equity grants, particularly RSUs with dividend equivalents, are a common compensation practice for senior executives in large-cap pharmaceutical companies like Amgen, comparable to practices at industry peers such as Pfizer, Johnson & Johnson, and Merck.
• The structure of these grants typically aims to retain key talent and motivate performance over multi-year vesting periods, aligning with global benchmarks for executive incentive programs in the life sciences sector.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Positive impact due to increased alignment of executive interests with long-term company performance and value creation.
• Employees: No direct impact mentioned in this filing.
• Customers/Suppliers/Creditors: No direct impact mentioned in this filing.

Next Steps

• NA

Key Dates

Recommendation

This Form 4 reports a standard equity grant to a key executive, which is a routine compensation event and does not provide new information that would alter the fundamental investment outlook for Amgen. It reinforces management alignment but does not signal a change in company prospects that would warrant a change in investment recommendation.

Keywords

Amgen, AMGN, Form 4, insider transaction, equity grant, common stock, Peter H. Griffith, CFO, executive compensation, RSU, dividend equivalents